Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epaminurad + naproxen
- Development stage
- Phase 1
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Epaminurad + naproxen is a combination of two small molecule drugs. Epaminurad (also known as SIM0295) is a novel inhibitor of human uric acid transporter 1 (hURAT1), developed for the treatment of gout and hyperuricemia[4]. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that works by reversibly inhibiting both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), leading to decreased prostaglandin synthesis and resulting in reduced inflammation and pain[2][6][8]. The combination may be used to address both the underlying hyperuricemia/gout with epaminurad and the associated pain/inflammation with naproxen.
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on Epaminurad + naproxen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epaminurad + naproxen.